Journal for ImmunoTherapy of Cancer (Nov 2020)

211 Targeting BTN2A1 modulates anti-tumor activity of Vg9Vd2 T cells

Carla Cano,
Aude de Gassart,
Christine Pasero,
Melanie Gabriac,
Marie Fullana,
Emilie Granarolo,
HOET Rene,
Caroline Imbert,
Laurent Gorvel,
Antoine Briantais,
Anne-Charlotte Le Floch,
Daniel Olive

Affiliations

Carla Cano: 1ImCheck Therapeutics, Marseille, France
Aude de Gassart: 1ImCheck Therapeutics, Marseille, France
Christine Pasero: 1ImCheck Therapeutics, Marseille, France
Melanie Gabriac: 1ImCheck Therapeutics, Marseille, France
Marie Fullana: 1ImCheck Therapeutics, Marseille, France
Emilie Granarolo: 1ImCheck Therapeutics, Marseille, France
HOET Rene: 1ImCheck Therapeutics, Marseille, France
Caroline Imbert: 1ImCheck Therapeutics, Marseille, France
Laurent Gorvel: 2CRCM, Marseille, France
Antoine Briantais: 2CRCM, Marseille, France
Anne-Charlotte Le Floch: 2CRCM, Marseille, France
Daniel Olive: 2CRCM, Marseille, France

DOI: https://doi.org/10.1136/jitc-2020-SITC2020.0211
Journal volume & issue: Vol. 8, no. Suppl 3

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal